The African Journal of Pharmaceutical Sciences and Pharmacy AJPSP 2:1, 114-144, APRIL 30, 2011
Non-invasive Systemic Drug Delivery via Nasal Route: A Review Ram Chand Dhakar* Dept. of Pharmacy, Indian Education Centre, Group of Institution, KP-1, G. Noida, India -201308 *
Corresponding author email:
[email protected]
ABSTRACT Transmucosal nasal delivery is a promising drug delivery option where common drug administrations, such as intravenous, intramuscular, or oral are inapplicable. Recently, it has been shown that many drugs have better bioavailability by nasal route than the oral route. This has been attributed to rich vasculature and a highly permeable structure of the nasal mucosa coupled with avoidance of hepatic first-pass elimination, gut wall metabolism and/or destruction in the gastrointestinal tract. The physiology of the nose presents obstacles, but offers a promising route for non-invasive systemic delivery of numerous therapies and debatably drug delivery route to the brain. Intranasal microemulsions, gels and microspheres have gained increased interest in recent years as a delivery system for protein and peptides through the nasal route. Thus this review focuses on nasal drug delivery, various aspects of nasal anatomy and physiology, nasal drug absorption mechanisms, various nasal drug delivery systems, and their applications in drug delivery.
KEYWORDS: Transmucosal nasal delivery, Hepatic first-pass metabolism, Non-invasive, microemulsions, Microspheres AJPSP 2011; 2:1
Ram Chand Dhakar Page 114
African Journal of Pharmaceutical Sciences and Pharmacy 2011; 2:1
AJPSP: African Journal of Pharmaceutical Sciences and Pharmacy
INTRODUCTION Oral drug delivery is the most desirable route for drug administration whenever systemic effects are intended (1, 2). Low oral bioavailability of some compounds however, has prompted the search of more effective routes for their systemic delivery (3). Transmucosal routes of drug delivery (i.e., the mucosal linings of the nasal, rectal, vaginal, ocular and oral cavity) offer distinct advantages over per oral administration for systemic drug delivery. These advantages include possible bypass of the first pass effect mechanism, avoidance of pre-systemic elimination of the gastrointestinal tract, depending on the particular drug. The nasal cavity as a site for systemic drug delivery has been investigated by many research groups and the route has already reached commercial status with several drugs, including calcitonin (4-10, 11, 12). The potential irritation and irreversible damage to the ciliary action application of nasal dosage forms, as well as the large intra and inter subject variability in mucus secretion in the nasal mucosa could significantly affect drug absorption from this site. Currently, many nasal drug products on the market are indicated in the treatment of local diseases such as allergic rhinitis, pain, and for centrally acting drugs where the direct pathway from the nose to brain might offer a quicker and further specific therapeutic effect. Many low-molecularweight, non-polar drugs (
